Who founded Cognigenics?

Cognigenics was founded by John Mee in 2021.

Who are Cognigenics's investors?

Cognigenics's investors include LIONHEART VENTURES.

How much funding has Cognigenics raised?

Cognigenics has disclosed $1.6M raised across 1 round.

Where is Cognigenics headquartered?

Cognigenics is headquartered in Eagle, US.

Cognigenics

Eagle, US · Founded 2021 · Delaware corporation · 1 known investors

Cognigenics is developing iRNAi, a non-invasive intranasal RNA interference platform that delivers programmable RNA therapeutics directly to targeted brain circuits, bypassing the blood-brain barrier to modulate mood, memory, and cognition. The company focuses on precision neuropsychiatry and treatments for neurological and psychiatric disorders.

Biotech Deep Tech Digital Health

Founders & leadership

Cognigenics was founded in 2021 by John Mee.

John MeeMr. Mee is a promoter, director and officer of the company.

Barry LinderNamed on SEC filing

Dean RadinNamed on SEC filing

Investors · 1

LIONHEART VENTURESSan Francisco

Reported raises · per SEC filings

Form D private placements

$1.6M disclosed across 1 round · 2022

▶$1.6MraisedAug 2022 · 3 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

John MeeExecutive Officer, Director, Promoter
Barry LinderExecutive Officer, Director, Promoter
Dean RadinExecutive Officer, Director, Promoter

Offering amount: $1.6M
Amount sold: $1.6M
Minimum investment: $442K
First sale: Jun 2022
Incorporated: Corporation, Delaware, 2021
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 2

by search overlap

Bioworld22 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.

Cognito TX16 shared keywordsCognito Therapeutics develops Spectris, a non-invasive sensory stimulation technology platform to treat neurodegenerative diseases including Alzheimer's by improving cognitive performance. The company serves patients with neurodegenerative conditions and aims to transform disease management through clinical-to-commercial pathways in the neurological therapeutics sector.

Companies competing with Cognigenics for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does Cognigenics do?: Cognigenics is developing iRNAi, a non-invasive intranasal RNA interference platform that delivers programmable RNA therapeutics directly to targeted brain circuits, bypassing the blood-brain barrier to modulate mood, memory, and cognition. The company focuses on precision neuropsychiatry and treatments for neurological and psychiatric disorders.
Who founded Cognigenics?: Cognigenics was founded by John Mee in 2021.
Who are Cognigenics's investors?: Cognigenics's investors include LIONHEART VENTURES.
How much funding has Cognigenics raised?: Cognigenics has disclosed $1.6M raised across 1 round.
Where is Cognigenics headquartered?: Cognigenics is headquartered in Eagle, US.